Education
About Us
Working with TipRanks
Follow Us
BioVersys AG (CH:BIOV)
:BIOV
BIOV Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF24.40 - CHF37.00
Previous CloseN/A
Volume262.00
Average Volume (3M)4.59K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Apr 01, 2026EPS Estimate
-3.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding5,843,986
10 Day Avg. Volume3,255
30 Day Avg. Volume4,592
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioVersys AG News
BIOV FAQ
What was BioVersys AG’s price range in the past 12 months?
BioVersys AG lowest stock price was CHF24.40 and its highest was CHF37.00 in the past 12 months.
What is BioVersys AG’s market cap?
Currently, no data Available
When is BioVersys AG’s upcoming earnings report date?
BioVersys AG’s upcoming earnings report date is Apr 01, 2026 which is in 196 days.
How were BioVersys AG’s earnings last quarter?
BioVersys AG released its earnings results on Sep 10, 2025. The company reported -CHF2.05 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF2.05.
Is BioVersys AG overvalued?
According to Wall Street analysts BioVersys AG’s price is currently Overvalued.
Does BioVersys AG pay dividends?
BioVersys AG does not currently pay dividends.
What is BioVersys AG’s EPS estimate?
BioVersys AG’s EPS estimate is -3.35.
How many shares outstanding does BioVersys AG have?
BioVersys AG has 5,843,986 shares outstanding.
What happened to BioVersys AG’s price movement after its last earnings report?
BioVersys AG reported an EPS of -CHF2.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.236%.
Which hedge fund is a major shareholder of BioVersys AG?
Currently, no hedge funds are holding shares in CH:BIOV
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
RELIEF THERAPEUTICS Holding
―
Options Prices
Currently, No data available
---